Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;155(3&4):335-346.
doi: 10.4103/ijmr.IJMR_312_19.

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

Fatemeh Saffari  1 , Abdollah Jafarzadeh  2
Affiliations
Review

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

Fatemeh Saffari et al. Indian J Med Res. 2022 Mar.

Abstract

The utilization of the monoclonal antibodies (mAbs) as therapeutic agents is one of the most favourable fields in immunotherapy. The immunogenicity of mAbs is one of the major parameters that may restrict their therapeutic and diagnostic applications. Rituximab, a chimeric mAb against CD20, is attached to the B-cell membrane-linked CD20 and is used to treat some B-cell-related malignancies, a number of autoantibody-mediated autoimmune disorders and improvement of graft survival. The risk of anti-rituximab antibody (ARA) development and ARA-related adverse events are low in rituximab-treated patients with lymphoma. No important association was reported between the ARA positivity and drug levels, and drug efficacy in rituximab-treated patients with lymphoma. The patients with autoimmune disorders exhibit greater risk of ARA development and ARA-related adverse events. In autoimmune diseases, ARA positivity may have no significant impact on either the drug level or its efficacy, (i.e.), it may reduce drug levels without influencing drug efficacy and, vice versa, or may reduce both drug level as well as its efficacy. The characterization of the parameters affecting the production of ARA can be used to design strategies to reduce the immunogenicity of mAb and promote its efficacy in humans. In this review, the host and therapeutic programme-related parameters affecting the development of the ARA have been discussed to suggest novel insights to reduce ARA-associated adverse events and enhance the drug efficacy.

Keywords: Anti-rituximab antibody; immunogenicity; immunotherapy; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sathyanarayanan V, Neelapu SS. Cancer immunotherapy:Strategies for personalization and combinatorial approaches. Mol Oncol. 2015;9:2043–53. - PMC - PubMed
    1. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies:Residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–65. - PMC - PubMed
    1. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11:20–33. - PMC - PubMed
    1. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14. - PMC - PubMed
    1. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clin. 2015;3:280–8. - PMC - PubMed